Anti-CD19 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy

Alternative Names: CAR-CD19-modified T cells; CD19-targeted CAR-T cells

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinobioway Cell Therapy
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Clinical Phase Unknown Lymphoma

Most Recent Events

  • 10 Apr 2018 Clinical trials in Lymphoma (Recurrent) in China (Parenteral) (NCT03488160)
  • 10 Apr 2017 Sinobioway Cell Therapy and Jiangsu Cancer Institute & Hospital plan a phase I trial for B-cell lymphoma (Second-line therapy or greater, CD19 positive) in China (NCT03086954)
  • 02 Jul 2015 Phase-II clinical trials in Diffuse large B cell lymphoma (Recurrent, Refractory metastatic disease) in China (Parenteral) (NCT02728882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top